| Old Articles: <Older 7861-7870 Newer> |
|---|
 |
The Motley Fool
September 9, 2011
Brandon Glenn |
Cardinal Health Looks to PET Drugs to Drive Margins The nuclear medicine business is an important driver of higher margins for the drug distribution company.   |
The Motley Fool
September 8, 2011
Brian Orelli |
All Approvals Are Not Created Equal MELA's EU approval for its skin cancer detector MelaFind isn't nearly as important as one stateside would be. |
The Motley Fool
September 8, 2011
Brian Orelli |
Delayed Data Coming Soon? EXELent! Exelixis should have data on cabozantinib early in the fourth quarter. |
The Motley Fool
September 8, 2011
Rex Moore |
Cepheid Seems Solid With These 2 Metrics Cepheid appears to be in good shape in terms of the intangible assets ratio and tangible book value. |
The Motley Fool
September 8, 2011
Arlene Weintraub |
Bristol-Pfizer Team on Alert as FDA Reviews Stroke-Prevention Drug From Rivals J&J and Bayer Who will come out ahead? |
The Motley Fool
September 7, 2011
Brian Orelli |
J&J and Bayer Head in Front of the Firing Squad An expanded indication for Xarelto seems unlikely. |
The Motley Fool
September 6, 2011
Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
The Motley Fool
September 6, 2011
Seth Jayson |
1 Reason the Street Should Expect Big Things From ViroPharma On a trailing-12-month basis, raw materials inventory was the fastest-growing segment, up 119.9%. |
The Motley Fool
September 6, 2011 |
1 Hot Stock to Avoid Our investing community's latest prime pick to avoid -- Star Scientific, which is a combination healthcare-tobacco company. |
The Motley Fool
September 3, 2011
Seth Jayson |
A Hidden Reason Why the Future Looks Bright for Jazz Pharmaceuticals Jazz Pharmaceuticals seems to be handling inventory well enough, but the individual segments don't provide a clear signal. |
| <Older 7861-7870 Newer> Return to current articles. |
